Last reviewed · How we verify

Complicated Skin and Skin Structure Streptococcus Pyogenes Infection — Treatment Landscape & Competitive Intelligence

Complicated Skin and Skin Structure Streptococcus Pyogenes Infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Skin and Skin Structure Streptococcus Pyogenes Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vibativ TELAVANCIN HYDROCHLORIDE Cumberland Lipoglycopeptide Antibacterial 2009-01-01
Vibativ TELAVANCIN Cumberland Lipoglycopeptide Antibacterial 2009-01-01
Tygacil Tigecycline Pfizer Tetracycline Bacterial protein synthesis 2005-01-01
Cubicin Daptomycin Baxter lipopeptide antibacterial 2003-01-01
Invanz ERTAPENEM Merck & Co. Penem Antibacterial 2001-01-01
Zyvox linezolid Pfizer Oxazolidinone Antibacterial [EPC] Amine oxidase [flavin-containing] A 2000-01-01
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Cubicin Cubicin Clinical Alliance for Research & Education - Infectious Diseases, LLC. Outer membrane porin protein OmpD
DAPT DAPT Baxter Hlthcare Corp Outer membrane porin protein OmpD
Ofloxacine Ofloxacine Assistance Publique - Hôpitaux de Paris Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  2. Cumberland · 2 drugs in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  3. · 2 drugs in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  4. Baxter Hlthcare Corp · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  5. Clinical Alliance for Research & Education - Infectious Diseases, LLC. · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  6. Merck & Co. · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  7. Fresenius Kabi · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  8. Generic (originally Daiichi Sankyo/J&J) · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
  10. Baxter · 1 drug in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Skin and Skin Structure Streptococcus Pyogenes Infection:

Cite this brief

Drug Landscape (2026). Complicated Skin and Skin Structure Streptococcus Pyogenes Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-skin-and-skin-structure-streptococcus-pyogenes-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing